Objective
CONSERT will integrate leading European activities for a structured implementation of novel therapies using genetically enhanced postnatal stem cells, with focus on the treatment of monogenic immunodeficiencies, hemoglobinopathies, anemias and storage disorders.
CONSERT will develop and evaluate methods for genetic stem cell modification with wide implications for many other disorders including viral infection and cancer. A central theme of the project is an unbiased safety and efficiency evaluation of the key technology used in the genetic modifications of replicating somatic cells: retroviral vector-mediated transgenesis. This is only possible through concerted multi-center studies. Lenti-, spuma- and gamma-retroviral vectors will be tailor-made for target disorders and tested for potency and safety in preclinical disease models. Designed with a translational aim, basic studies in stem cell biology and selectable marker technology will complement this research. A most important aspect of CONSERT is the molecular and clinical monitoring of currently active and successful clinical trials of genetic therapies. This will create a paradigmatic data-mining activity to obtain insights into crucial issues of clonal kinetics of gene-modified cells in vivo. Molecular studies in precise cell systems and animal models will provide the mechanistic understanding of transgene-host interactions. This project will generate the basis for technology development and promote patient safety. Translational dissemination of know-how from academia to industry will create a network of cell processing manufacturers with large economic potential, and prepare future clinical studies with improved predictability. Supervised by a proactive ethical project, CONSERT will stimulate a competitive and complementary evolution of biomedical academia, clinics, innovative health service providers, and associated training opportunities.
Fields of science
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- natural sciencesbiological sciencescell biology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineoncology
- medical and health sciencesclinical medicinehematology
Keywords
Topic(s)
Call for proposal
FP6-2003-LIFESCIHEALTH-I
See other projects for this call
Funding Scheme
IP - Integrated ProjectCoordinator
ROTTERDAM
Netherlands
See on map
Participants (23)
HANNOVER
See on map
IDAR-OBERSTEIN
See on map
BONN
See on map
KONSTANZ
See on map
BARCELONA
See on map
MADRID
See on map
PARIS
See on map
EVRY
See on map
MONTROUGE
See on map
ATHENS
See on map
MILAN
See on map
MILAN
See on map
MILAN
See on map
ROTTERDAM
See on map
LUND
See on map
LONDON
See on map
MANCHESTER
See on map
ATHENS
See on map
FRANKFURT AM MAIN
See on map
BRUSSELS
See on map
HEIDELBERG
See on map
LAUSANNE
See on map
FREIBURG
See on map